At last year’s Oracle Industry Connect conference, we heard from Jerry Whaley from Pfizer and several of our Coalition members about the value that ALSC brings to them in their quest for releasing new drugs to the market. Jerry said, “We are morally obligated for speed,” which is a statement that has been in my mind ever since.
As I arrived at this year’s Oracle Industry Connect (OIC) in Orlando, Fl, his statement was ever-present. Yet as I watched panels and keynotes alike, I noted questions that dominated so much time last year seemed long forgotten. I was hearing a new theme more consistently—knowing that the tools exist, how do we use them to optimize our business and get smarter? In short, how do we innovate, challenge and develop?
This year’s conference agenda for Health Sciences brought with it a refreshing line up of industry peers from a range of organizations. It challenged us to think about the lives of our patients—and in a world gripped with the frenzy of automated personal assistants, AI and where mobile is becoming the norm for day to day interaction, greater focus must now be placed on how we leverage these capabilities to create better visibility of the data that drives our businesses, and ultimately drives better patient outcomes.
The multi-company nature of the panels and keynotes at the conference is a great example of an industry with its principles set, ready to collaborate as we break free from previous limitations through innovation. The need for collaboration was a critical element brought to the forefront of our own panel event, with Shelley Padgett, from Eli Lilly, saying, “In a Coalition of like-minded companies, you have multiple hands working towards a common goal... we have the ability to stand up a full functioning capability that we may not have otherwise had.” Through these working relationships we're doing better than just managing and analyzing our data; we're pushing the boundaries to simplify and rapidly accelerate the speed with which patient data is collected, directly from the patient, processed, and autonomously analyzed. Through advanced AI capabilities, this analysis is becoming laser-focused on the most important exceptions that need managing and, of course, on where the most positive cases demand our attention be directed. And the scope of available day-to-day technology is enabling us to provide a plethora of quality-of-life benefits to how we engage with these processes—whether that be the patient seeking to contribute their latest readings, or the CFO of our Biotech clients looking to get up-to-the-minute intelligence on study performance for a board meeting.
At the forefront of establishing truly end-to-end capabilities, the landscape seems broader—not in a way that makes it more challenging, but in a way that allows us to see a difference being made. We’ve demonstrated some of our latest capabilities and this gave us the opportunity to see reactions to real world patient data being collected and analyzed, in a patient-centric manner; through an engaging patient experience on their iPhone and direct to our ALSC platform through cloud services, in real-time. This isn't technology that's in development, it's here now!
As I look forward to Oracle Industry Connect in 2018, I'm buoyed by what I've seen the industry achieve in the last year and what I feel, through collaboration with the Coalition, we can achieve in the year to come. I'm also excited that we're able to see real-world examples of the patient being the focal point of drug development processes, so we can get life-saving treatments to them faster.